ArticleJournal of nanobiotechnology2026
EphB4-decorated biomimetic nanoparticles enhance osteoclast targeting and therapeutic effect in osteoporosis.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- How Emerging Nanomaterials are Effective in Bone Regeneration?International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The therapeutic efficacy of osteoporosis (OP) treatments is often limited by inadequate cellular precision and poor accumulation within the bone microenvironment. Although synthetic nanoparticles have been developed to address these challenges, they commonly face biological barriers such as rapid systemic clearance, inefficient transendothelial transport, and limited affinity for the complex bone niche. Here, we report on a biomimetic nanobiotechnology platform that integrates biological recognition with precision polymer engineering to overcome these limitations. We engineered a core-shell nanostructure consisting of a bilirubin-loaded Poly D L-Lactide-co-glycolide (PLGA) core cloaked with genetically modified osteoblast (OB)-derived membranes overexpressing the Ephrin type-B receptor 4 (EphB4) receptor. This biomimetic nanoparticle (NP) exploits the endogenous EphB4-EphrinB2 (EFNB2) signaling axis to achieve selective recognition and preferential uptake by EFNB2-expressing osteoclasts (OCs), displaying significantly higher internalization in OCs compared with mesenchymal stem cells (MSC), macrophages (Mφ), and OBs in vitro. Furthermore, the cell-membrane corona enables efficient transendothelial migration under inflammatory conditions, facilitating targeted delivery to OCs beyond the vascular endothelium. In vitro molecular analyses demonstrated that receptor-mediated NP uptake significantly suppressed key osteoclastogenic regulators, including nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1), cathepsin K, and matrix metalloproteinase-9 (MMP-9). In a preclinical OP model, systemic administration resulted in bone-specific accumulation and robust restoration of trabecular microarchitecture and bone mineral density (BMD). Collectively, this work demonstrates that interfacial nanoengineering can translate complex receptor-guided biological interactions into stable, high-performance nanotherapeutics for the precision treatment of skeletal disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.